Navigation Links
CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

KING OF PRUSSIA, Pa. and MARBURG, Germany, May 3, 2012 /PRNewswire/ -- CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement Therapy) program, the study will evaluate the pharmacokinetics, pharmacodynamics and safety of various doses of this presentation of C1-INH.

"We're enormously pleased that a range of therapy options is now available to treat HAE," said Bruce Zuraw, MD, Professor of Medicine at the University of California, San Diego, USA, and Chairman of the Steering Committee for the COMPACT program. "Yet, we know that a significant number of patients would prefer a preventive therapy that does not require intravenous infusions and that might offer fewer side effects than currently available treatments. We are confident this study will guide us in the development of this novel method of using C1-esterase inhibitor replacement for the routine prevention of HAE attacks."

The open-label study will enroll adult patients with HAE type I or II. After an initial intravenous injection of C1-INH, each participant will be assigned to receive a single subcutaneous injection of the volume-reduced formulation of C1-INH twice a week for four weeks. Subjects will participate in two such periods with two different doses of volume-reduced C1-INH. Throughout the study, researchers will monitor C1-INH levels in the blood, as well as assess the safety and tolerability of the formulation at different doses.

"As a pioneer in the development of subcutaneous immunoglobulin therapy, we are excited to apply our expertise and experience in the treatment of hereditary angioedema," said Russell Basser, Senior Vice President of Clinical Research and Development at CSL Behring. "Subcutaneous administration of C1-esterase inhibitor will represent another important advance for patients suffering from the frequent and often debilitating attacks of HAE."

About Hereditary Angioedema

Hereditary angioedema (HAE), due to decreased C1-esterase inhibitor (C1-INH), is caused by mutations in SERPING1, the gene coding for C1-INH. It is inherited in an autosomal dominant manner. Symptoms of HAE include recurring episodes of edema, or swelling, in the hands, the feet, the face, the abdomen and/or the larynx. Patients who have abdominal attacks of HAE can experience episodes of severe pain, diarrhea, nausea and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face and larynx can result in airway closure, asphyxiation, and, if untreated, death. Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1-INH.  For more information about HAE, please visit

CSL Behring has currently licensed treatments in Australia, Canada, Europe, Japan, the United States and several other countries in Asia and South America for treatment of acute attacks of HAE.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For information:

Media contact: Sheila A. Burke, CSL Behring, 610-878-4209 (US)

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
2. CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
3. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
6. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
7. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
8. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
9. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
10. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
11. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):